186 related articles for article (PubMed ID: 16330906)
41. Hospital policies for treatment of acute decompensated heart failure.
Vats V; DiDomenico RJ; Wojtynek JE; Theobald JC; Schumock GT
Ann Pharmacother; 2007 Apr; 41(4):562-7. PubMed ID: 17374618
[TBL] [Abstract][Full Text] [Related]
42. Outcomes associated with nesiritide administration for acute decompensated heart failure in the emergency department observation unit: a single center experience.
Styron JF; Jois-Bilowich P; Tallman T; Emerman C; Starling RC; Frank Peacock W
Congest Heart Fail; 2009; 15(3):103-7. PubMed ID: 19522957
[TBL] [Abstract][Full Text] [Related]
43. The ASCEND-HF trial: an acute study of clinical effectiveness of nesiritide and decompensated heart failure.
Dandamudi S; Chen HH
Expert Rev Cardiovasc Ther; 2012 May; 10(5):557-63. PubMed ID: 22651831
[TBL] [Abstract][Full Text] [Related]
44. Nesiritide in acute decompensated heart failure: current status and future perspectives.
Mohammed SF; Korinek J; Chen HH; Burnett JC; Redfield MM
Rev Cardiovasc Med; 2008; 9(3):151-8. PubMed ID: 18953274
[TBL] [Abstract][Full Text] [Related]
45. Rotating inotrope therapy in a pediatric population with decompensated heart failure.
Ryerson LM; Alexander PM; Butt WW; Shann FA; Penny DJ; Shekerdemian LS
Pediatr Crit Care Med; 2011 Jan; 12(1):57-60. PubMed ID: 20453705
[TBL] [Abstract][Full Text] [Related]
46. Improved mortality and haemodynamics with milrinone in cardiogenic shock due to acute decompensated heart failure.
Rodenas-Alesina E; Luis Scolari F; Wang VN; Brahmbhatt DH; Mihajlovic V; Fung NL; Otsuki M; Billia F; Overgaard CB; Luk A
ESC Heart Fail; 2023 Aug; 10(4):2577-2587. PubMed ID: 37322827
[TBL] [Abstract][Full Text] [Related]
47. Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol.
Lowes BD; Tsvetkova T; Eichhorn EJ; Gilbert EM; Bristow MR
Int J Cardiol; 2001 Dec; 81(2-3):141-9. PubMed ID: 11744130
[TBL] [Abstract][Full Text] [Related]
48. Rationale, design, and methods for the Transplant-Eligible MAnagement of Congestive Heart Failure (TMAC) trial: a multicenter clinical outcomes trial using nesiritide for TMAC.
Mehra MR; McCluskey T; Barr M; Bourge RC; Jessup ML; Mancini D; Radovancevic B; Rayburn B; Taylor DO; Lilly-Hersley J; Linde P
Am Heart J; 2007 Jun; 153(6):932-40. PubMed ID: 17540193
[TBL] [Abstract][Full Text] [Related]
49. Intraoperative milrinone versus dobutamine in cardiac surgery patients: a retrospective cohort study on mortality.
Nielsen DV; Torp-Pedersen C; Skals RK; Gerds TA; Karaliunaite Z; Jakobsen CJ
Crit Care; 2018 Feb; 22(1):51. PubMed ID: 29482650
[TBL] [Abstract][Full Text] [Related]
50. Chronic inotropic therapy in end-stage heart failure.
Hauptman PJ; Mikolajczak P; George A; Mohr CJ; Hoover R; Swindle J; Schnitzler MA
Am Heart J; 2006 Dec; 152(6):1096.e1-8. PubMed ID: 17161059
[TBL] [Abstract][Full Text] [Related]
51. The role of B-type natriuretic peptide in heart failure.
Nappi JM
Crit Care Nurs Clin North Am; 2003 Dec; 15(4):461-5. PubMed ID: 14717391
[TBL] [Abstract][Full Text] [Related]
52. Effect of nesiritide on length of hospital stay in patients with decompensated heart failure.
Chang R; Elatre WA; Heywood JT
J Cardiovasc Pharmacol Ther; 2004 Sep; 9(3):173-7. PubMed ID: 15378137
[TBL] [Abstract][Full Text] [Related]
53. Nesiritide utilization evaluation in a university teaching hospital.
Cheng JW; Merl MY; Nguyen HM; Caliendo GC; Meyers J
J Clin Pharm Ther; 2005 Oct; 30(5):447-53. PubMed ID: 16164491
[TBL] [Abstract][Full Text] [Related]
54. Science or fiction: use of nesiritide as a first-line agent?
Noviasky JA; Kelberman M; Whalen KM; Guharoy R; Darko W
Pharmacotherapy; 2003 Aug; 23(8):1081-3. PubMed ID: 12921256
[TBL] [Abstract][Full Text] [Related]
55. Prognostic Value of Baseline and Changes in Circulating Soluble ST2 Levels and the Effects of Nesiritide in Acute Decompensated Heart Failure.
Tang WH; Wu Y; Grodin JL; Hsu AP; Hernandez AF; Butler J; Metra M; Voors AA; Felker GM; Troughton RW; Mills RM; McMurray JJ; Armstrong PW; O'Connor CM; Starling RC
JACC Heart Fail; 2016 Jan; 4(1):68-77. PubMed ID: 26656144
[TBL] [Abstract][Full Text] [Related]
56. Morbidity and mortality of UNOS status 1B cardiac transplant candidates at home.
Lang CC; Hankins S; Hauff H; Maybaum S; Edwards N; Mancini DM
J Heart Lung Transplant; 2003 Apr; 22(4):419-26. PubMed ID: 12681419
[TBL] [Abstract][Full Text] [Related]
57. Practical application of human B-type natriuretic peptide as a therapeutic intervention in the perioperative setting.
Feldman DS; Sun B
Heart Fail Rev; 2004 Jul; 9(3):203-8. PubMed ID: 15809818
[TBL] [Abstract][Full Text] [Related]
58. Nesiritide: trials and tribulations.
Arora RR
J Cardiovasc Pharmacol Ther; 2006 Sep; 11(3):165-9. PubMed ID: 17056828
[TBL] [Abstract][Full Text] [Related]
59. Assessment of dyspnea in acute decompensated heart failure: insights from ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) on the contributions of peak expiratory flow.
Ezekowitz JA; Hernandez AF; O'Connor CM; Starling RC; Proulx G; Weiss MH; Bakal JA; Califf RM; McMurray JJ; Armstrong PW
J Am Coll Cardiol; 2012 Apr; 59(16):1441-8. PubMed ID: 22497823
[TBL] [Abstract][Full Text] [Related]
60. Clinical and hemodynamic effects of nesiritide (B-type natriuretic peptide) in patients with decompensated heart failure receiving beta blockers.
Abraham WT; Cheng ML; Smoluk G;
Congest Heart Fail; 2005; 11(2):59-64. PubMed ID: 15860969
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
